Silexion Therapeutics soars on preclinical cancer trial data
28/01/2025 14:13
** Shares of drug developer Silexion Therapeutics SLXN.O
rise ~125% to $1.30 premarket
** SLXN says preclinical trials of its cancer treatment,
SIL-204, shows significant reduction in tumor growth in
pancreatic cancer models
** SIL-204 reduced tumor growth by 50% and showed complete
necrosis in 50% of tumors in some trials
** Says SIL-204 was effective in inhibiting key
cancer-causing KRAS mutations and maintained effective drug
levels in the body for over 56 days
** SLXN fell 88.4% in 2024, since its Nasdaq debut on Aug.
16, 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))